Crizotinib shows antitumor activity, with a tolerable safety profile, in NSCLC with MET exon 14 alterations.
Evaluation of patients with metastatic NSCLC treated past first RECIST defined progression with anti–PD-1 therapy in clinical trials finds that a small proportion (8%) attained a subsequent response to treatment.
Concurrent CRT using modern RT techniques produced similar rates of survival and toxicity whether given once daily or twice daily for limited-stage SCLC.
DFS and OS outcomes similar in patients with early-stage, resected NSCLC for 4 different cisplatin-based doublet chemotherapy regimens tested.
Early phase data suggest that osimertinib is safe, tolerable, and produces clinical benefit in patients with difficult-to-treat NSCLC.
In oligometastatic NSCLC without progression after first-line systemic therapy, local consolidative therapy significantly improved PFS without increasing toxicity.
Brigatinib showed a 54% ORR with a median PFS > 1 year in patients with crizotinib-refractory ALK+ NSCLC.
J-ALEX met its primary endpoint--alectinib significantly improved PFS vs crizotinib with a favorable safety profile in ALK inhibitor–naive patients with ALK-positive NSCLC.
Lorlatinib is well tolerated in ALK+ and ROS1+ NSCLC and shows antitumor activity, including intracranial activity, in patients pretreated with available inhibitors of ALK and ROS1.
Treatment-experienced patients with rare RET-fusion driver mutations responded well to single-agent vandetanib in this small trial, with more than one half of patients achieving an objective response.
Here are the studies being presented at ASCO 2016 that David R. Gandara, MD, and I think are most likely to affect clinical practice in our patients with lung cancer.
David R. Gandara, MD, and Heather A. Wakelee, MD, review and analyze important lung cancer presentations from the 2016 clinical oncology meeting in Chicago.
In this phase I study, the antibody–drug conjugate rovalpituzumab tesirine demonstrated good response rates in patients with relapsed/refractory SCLC and high DLL3 expression, making it the first biomarker-directed therapy with activity in this disease.
In this downloadable slideset, David R. Gandara, MD, and Heather A. Wakelee, MD, review important lung cancer presentations from the 2016 clinical oncology meeting in Chicago.